Literature DB >> 17251538

Prophylaxis and aspergillosis--has the principle been proven?

Ben E De Pauw, J Peter Donnelly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17251538     DOI： 10.1056/NEJMe068266

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

1.  Azole prophylaxis to prevent invasive fungal infections in patients with severe graft-versus-host disease.

Authors:  Stanley W Chapman
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

2.  Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.

Authors:  Anne-Sophie Brunel; Agnieszka Wójtowicz; Frédéric Lamoth; Olivier Spertini; Dionysios Neofytos; Thierry Calandra; Oscar Marchetti; Pierre-Yves Bochud
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

3.  Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment.

Authors:  John W Baddley; Senu Apewokin
Journal:  Curr Fungal Infect Rep       Date:  2008-05-30

4.  Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Deniz Arıca; Demet Aydın; Naciye Demirel; Osman Yokuş
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

5.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Authors:  Michelle R Ananda-Rajah; Andrew Grigg; Maria T Downey; Ashish Bajel; Tim Spelman; Allen Cheng; Karin T Thursky; Janette Vincent; Monica A Slavin
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Authors:  Corrado Girmenia; Anna Maria Frustaci; Giuseppe Gentile; Clara Minotti; Claudio Cartoni; Saveria Capria; Silvia Maria Trisolini; Angela Matturro; Giuseppina Loglisci; Roberto Latagliata; Massimo Breccia; Giovanna Meloni; Giuliana Alimena; Robin Foà; Alessandra Micozzi
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

7.  Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience.

Authors:  H Gedik; M T Yildirmak; F Simsek; D Aydin; N Demirel; O Yokus; D Arica
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

8.  Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.

Authors:  Palash Samanta; Cornelius J Clancy; Rachel V Marini; Ryan M Rivosecchi; Erin K McCreary; Ryan K Shields; Bonnie A Falcione; Alex Viehman; Lauren Sacha; Eun Jeong Kwak; Fernanda P Silveira; Pablo G Sanchez; Matthew Morrell; Lloyd Clarke; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

9.  Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.

Authors:  Jeroen P Jansen; Amy K O'Sullivan; Elly Lugtenburg; Lambert F R Span; Jeroen J W M Janssen; Wiro B Stam
Journal:  Ann Hematol       Date:  2010-04-10       Impact factor: 3.673

10.  Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005.

Authors:  Konrad Donhuijsen; Peter Petersen; Werner Kurt Schmid
Journal:  Dtsch Arztebl Int       Date:  2008-07-14       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.